Insmed (INSM) Revenue & Revenue Breakdown
Insmed Revenue Highlights
Latest Revenue (Y)
$305.21M
Latest Revenue (Q)
$93.42M
Main Geography (Y)
UNITED STATES
Insmed Revenue by Period
Insmed Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $305.21M | 24.39% |
2022-12-31 | $245.36M | 30.19% |
2021-12-31 | $188.46M | 14.63% |
2020-12-31 | $164.41M | 20.48% |
2019-12-31 | $136.47M | 1287.56% |
2018-12-31 | $9.84M | 100.00% |
2017-12-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2015-12-31 | - | -100.00% |
2014-12-31 | $11.50M | - |
2013-12-31 | $11.50M | 100.00% |
2012-12-31 | - | -100.00% |
2011-12-31 | $4.42M | -36.18% |
2010-12-31 | $6.92M | -33.28% |
2009-12-31 | $10.37M | -11.33% |
2008-12-31 | $11.70M | 55.39% |
2007-12-31 | $7.53M | 659.74% |
2006-12-31 | $991.00K | 656.49% |
2005-12-31 | $131.00K | -4.38% |
2004-12-31 | $137.00K | -8.67% |
2003-12-31 | $150.00K | -92.33% |
2002-12-31 | $1.96M | 560.47% |
2001-12-31 | $296.00K | 393.33% |
2000-12-31 | $60.00K | -90.95% |
1999-12-31 | $663.16K | - |
Insmed Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $93.42M | 3.41% |
2024-06-30 | $90.34M | 19.66% |
2024-03-31 | $75.50M | -9.79% |
2023-12-31 | $83.69M | 5.84% |
2023-09-30 | $79.07M | 2.39% |
2023-06-30 | $77.23M | 18.42% |
2023-03-31 | $65.21M | 9.97% |
2022-12-31 | $59.30M | -12.45% |
2022-09-30 | $67.73M | 3.85% |
2022-06-30 | $65.22M | 22.81% |
2022-03-31 | $53.11M | -5.38% |
2021-12-31 | $56.12M | 20.03% |
2021-09-30 | $46.76M | 3.07% |
2021-06-30 | $45.37M | 12.81% |
2021-03-31 | $40.21M | -2.90% |
2020-12-31 | $41.41M | -5.11% |
2020-09-30 | $43.64M | 2.70% |
2020-06-30 | $42.49M | 15.29% |
2020-03-31 | $36.86M | -19.36% |
2019-12-31 | $45.71M | 17.55% |
2019-09-30 | $38.88M | 29.74% |
2019-06-30 | $29.97M | 36.85% |
2019-03-31 | $21.90M | 122.69% |
2018-12-31 | $9.84M | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | 100.00% |
2017-03-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2016-09-30 | - | 100.00% |
2016-06-30 | - | 100.00% |
2016-03-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2015-09-30 | - | 100.00% |
2015-06-30 | - | 100.00% |
2015-03-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2014-09-30 | - | 100.00% |
2014-06-30 | - | 100.00% |
2014-03-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2013-09-30 | - | -100.00% |
2013-06-30 | $11.50M | 100.00% |
2013-03-31 | - | 100.00% |
2012-12-31 | - | 100.00% |
2012-09-30 | - | 100.00% |
2012-06-30 | - | 100.00% |
2012-03-31 | - | -100.00% |
2011-12-31 | $1.40M | 222.53% |
2011-09-30 | $435.00K | -55.52% |
2011-06-30 | $978.00K | -38.91% |
2011-03-31 | $1.60M | 21.20% |
2010-12-31 | $1.32M | -26.90% |
2010-09-30 | $1.81M | -3.06% |
2010-06-30 | $1.86M | -3.37% |
2010-03-31 | $1.93M | -22.47% |
2009-12-31 | $2.49M | 0.53% |
2009-09-30 | $2.48M | -18.59% |
2009-06-30 | $3.04M | 28.27% |
2009-03-31 | $2.37M | -17.10% |
2008-12-31 | $2.86M | -29.77% |
2008-09-30 | $4.07M | 53.74% |
2008-06-30 | $2.65M | 14.29% |
2008-03-31 | $2.32M | 8.17% |
2007-12-31 | $2.14M | - |
Insmed Revenue Breakdown
Insmed Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 23 | Dec 22 | Dec 21 |
---|---|---|---|
Europe And The Rest Of The World | $15.28M | $2.86M | $12.95M |
UNITED STATES | $224.19M | $185.99M | $159.51M |
JAPAN | $65.73M | $56.51M | $16.01M |
Latest
Quarterly Revenue by Country
Country | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
---|---|---|---|---|---|---|---|---|---|---|
JAPAN | $20.98M | $14.89M | $20.95M | $16.03M | $15.59M | $13.16M | $15.50M | $14.48M | $15.85M | $10.68M |
UNITED STATES | $66.87M | $56.35M | $58.26M | $59.20M | $57.66M | $49.07M | $48.48M | $49.54M | $47.19M | $3.53M |
Europe And The Rest Of The World | $5.57M | $4.26M | $4.48M | $3.84M | $3.97M | $2.99M | $-4.68M | $3.71M | $2.18M | $-1.31M |
Latest
Insmed Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
BGNE | BeiGene | $2.46B | $929.17M |
HALO | Halozyme Therapeutics | $829.25M | $290.08M |
HRMY | Harmony Biosciences | $582.02M | $186.04M |
RARE | Ultragenyx Pharmaceutical | $434.25M | $147.03M |
APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
INSM | Insmed | $305.21M | $93.42M |
ASND | Ascendis Pharma | $266.72M | $95.89M |
BPMC | Blueprint Medicines | $249.38M | $128.18M |
AGIO | Agios Pharmaceuticals | $26.82M | $8.96M |
FENC | Fennec Pharmaceuticals | $21.64M | $6.97M |
RVMD | Revolution Medicines | $11.58M | - |
RNA | Avidity Biosciences | $9.56M | $2.04M |
JANX | Janux Therapeutics | $8.08M | $8.90M |
SWTX | SpringWorks Therapeutics | $5.45M | $59.73M |
KROS | Keros Therapeutics | $151.00K | $37.00K |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
AKRO | Akero Therapeutics | - | - |
EWTX | Edgewise Therapeutics | - | - |